Catalyst
Slingshot members are tracking this event:
FDA Approves GBT's (GBT) Supplemental New Drug Application for Expanded Indication of Oxbryta (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GBT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 17, 2021
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Voxelotor, Oxbryta, Sickle Cell Disease
